Regeneron Pharmaceuticals Inc (REGN)
762.61
+5.80
(+0.77%)
USD |
NASDAQ |
Nov 18, 16:00
762.61
0.00 (0.00%)
After-Hours: 19:33
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 83.80B |
| 52 Week High (Daily) | Upgrade |
| 52 Week Low (Daily) | Upgrade |
| All-Time High (Daily) | Upgrade |
| Year to Date Total Returns (Daily) | Upgrade |
| 1 Month Total Returns (Daily) | Upgrade |
| 1 Year Total Returns (Daily) | -4.49% |
| Valuation | |
| PE Ratio | 18.87 |
| PE Ratio (Forward) | Upgrade |
| PS Ratio | 6.339 |
| Price to Book Value | 2.858 |
| EV to EBITDA | Upgrade |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | Upgrade |
| Financials | |
| Revenue (5 Year Growth) | Upgrade |
| Revenue (Quarterly YoY Growth) | Upgrade |
| EPS Diluted (5 Year Growth) | Upgrade |
| EPS Diluted (Quarterly YoY Growth) | Upgrade |
| Debt to Equity Ratio | 0.0677 |
| Return on Equity | Upgrade |
| Return on Assets | Upgrade |
| Risk | |
| Beta (5Y) | Upgrade |
| Max Drawdown (5Y) | 43.25% |
Profile
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
| URL | https://www.regeneron.com |
| Investor Relations URL | https://investor.regeneron.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Ratings
Profile
| Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; and Kevzara in rheumatoid arthritis. Regeneron is also developing monoclonal and bispecific antibodies with Sanofi, other collaborators, and independently, and has earlier-stage partnerships that bring new technology to the pipeline, including RNAi (Alnylam) and Crispr-based gene editing (Intellia). |
| URL | https://www.regeneron.com |
| Investor Relations URL | https://investor.regeneron.com/ |
| HQ State/Province | New York |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Large Cap/Value |
| Next Earnings Release | Jan. 31, 2025 (est.) |
| Last Earnings Release | Oct. 31, 2024 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |